Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes

Pharmaceutical Research

Volumn 28, Issue 8, 2011, Pages 2008-2019

  Kim, Hyunuk ^a   Lee, Juho ^a   Kim, Tae Hyung ^b   Lee, Eun Seong ^c   Oh, Kyung Taek ^d   Lee, Don Haeng ^e   Park, Eun Seok ^b   Bae, You Han ^f   Lee, Kang Choon ^b   Youn, Yu Seok ^a  

^a Pusan National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Chung Ang University   (South Korea)

^e Inha University   (South Korea)

^f UNIVERSITY OF UTAH   (United States)

Author keywords

albumin binding; albumin coating; inhalation; palmityl acylated exendin 4; porous microspheres

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALBUMIN; EXENDIN 4; MALEIC ANHYDRIDE; POLYETHYLENE; POLYGLACTIN;

AERATION; AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EMULSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG INJURY; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; POROSITY; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

ADMINISTRATION, INHALATION; ALBUMINS; ANIMALS; CELL LINE, TUMOR; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; EMULSIFYING AGENTS; ETHYLDIMETHYLAMINOPROPYL CARBODIIMIDE; HUMANS; HYPOGLYCEMIC AGENTS; LACTIC ACID; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICROSPHERES; PALMITIC ACIDS; PARTICLE SIZE; PEPTIDES; POLYGLYCOLIC ACID; POROSITY; VENOMS;

EID: 79961172157     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0427-4     Document Type: Article

References (43)

1. JL Cleland A Daugherty R Mrsny 2001 Emerging protein delivery methods Curr Opin Biotechnol 12 2 212 219 11287240 10.1016/S0958-1669(00)00202-0 1:CAS:528:DC%2BD3MXjt1Oksr0%3D (Pubitemid 32247411)
2. Ho RJY, Gibaldi M. Advanced drug delivery. In: Ho RJY, Gibaldi M, editors. Biotechnology and biopharmaceuticals. Wiley-Liss; 2003. p. 339-80.
3. GP Carino E Mathiowitz 1999 Oral insulin delivery Adv Drug Deliv Rev 35 2-3 249 257 10837700 10.1016/S0169-409X(98)00075-1 1:CAS:528: DyaK1MXksFehuw%3D%3D (Pubitemid 29073617)
4. YS Youn MJ Kwon DH Na SY Chae S Lee KC Lee 2008 Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection J Control Release 125 1 68 75 18023905 10.1016/j.jconrel.2007.10.008 1:CAS:528:DC%2BD2sXhsVSisb%2FJ (Pubitemid 350198681)
5. JS Patton CS Fishburn JG Weers 2004 The lungs as a portal of entry for systemic drug delivery Proc Am Thorac Soc 1 4 338 344 16113455 10.1513/pats.200409-049TA 1:CAS:528:DC%2BD28XhsFGjsLs%3D
6. RU Agu MI Ugwoke M Armand R Kinget N Verbeke 2001 The lung as a route for systemic delivery of therapeutic proteins and peptides Respir Res 2 4 198 209 11686885 10.1186/rr58 1:CAS:528:DC%2BD3MXosVWmsro%3D (Pubitemid 34187927)
7. JS Patton PR Byron 2007 Inhaling medicines: delivering drugs to the body through the lungs Nat Rev Drug Discov 6 1 67 74 17195033 10.1038/nrd2153 1:CAS:528:DC%2BD28XhtlGktbbL (Pubitemid 46020287)
8. Adjei A, Adjei AL, Gupta PK. Inhalation delivery of therapeutic peptides and proteins. New York: Marcel Dekker Inc.; 1997. p. 107-15.
9. S Freiberg XX Zhu 2004 Polymer microspheres for controlled drug release Int J Pharm 282 1-2 1 18 15336378 10.1016/j.ijpharm.2004.04.013 1:CAS:528:DC%2BD2cXntVGhs7o%3D (Pubitemid 39178480)
10. ES Lee MJ Kwon H Lee K Na JJ Kim 2006 In vitro study of lysozyme in poly(lactide-co-glycolide) microspheres with sucrose acetate isobutyrate Eur J Pharm Sci 29 5 435 441 16978848 10.1016/j.ejps.2006.08.005 1:CAS:528: DC%2BD28XhtF2qur3M (Pubitemid 44709866)
11. MJ Kwon JH Bae JJ Kim K Na ES Lee 2007 Long acting porous microparticles for pulmonary drug delivery Int J Pharm 333 1-2 5 9 17296275 10.1016/j.ijpharm.2007.01.016 1:CAS:528:DC%2BD2sXitFSjsrY%3D (Pubitemid 46283284)
12. ES Lee MJ Kwon K Na JH Bae 2007 Protein release behavior from porous microparticle with lysozyme/hyaluronate ionic complex Colloids Surfs B 55 1 125 130 10.1016/j.colsurfb.2006.11.024 1:CAS:528:DC%2BD2sXhs1Smtr0%3D (Pubitemid 46216069)
13. DA Edwards J Hanes G Caponetti J Hrkach A Ben-Jebria ML Eskew, et al. 1997 Large porous particles for pulmonary drug delivery Science 276 5320 1868 1871 9188534 10.1126/science.276.5320.1868 1:CAS:528:DyaK2sXksVCmsr4%3D (Pubitemid 27443665)
14. DA Edwards A Ben-Jebria R Langer 1998 Recent advances in pulmonary drug delivery using large, porous inhaled particles J Appl Physiol 85 2 379 385 9688708 1:CAS:528:DyaK1cXlsFGgtLc%3D (Pubitemid 28365799)
15. Youn YS, Lee KC, Bae YH, Na K, Lee ES. Advanced pulmonary delivery of peptides or proteins using polymeric particles. In: Jorgensen L, Nielson HM, editors. Delivery technologies for biopharmaceuticals: Peptides, proteins, nucleic acids, and vaccines. WILEY; 2009. p. 228-44.
16. HK Kim HJ Chung TG Park 2006 Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone J Control Release 112 2 167 174 16542746 10.1016/j.jconrel.2006.02.004 1:CAS:528:DC%2BD28XktVWns7Y%3D
17. Y Yang N Bajaj P Xu K Ohn MD Tsifansky Y Yeo 2009 Development of highly porous large PLGA microparticles for pulmonary drug delivery Biomaterials 30 10 1947 1953 19135245 10.1016/j.biomaterials.2008.12.044 1:CAS:528: DC%2BD1MXhvFahsbw%3D
18. TK Kim JJ Yoon DS Lee TG Park 2006 Gas foamed open porous biodegradable polymeric microspheres Biomaterials 27 2 152 159 16023197 10.1016/j. biomaterials.2005.05.081 (Pubitemid 41278516)
19. Available from: http://www.mannkindcorp.com/afresa-background.aspx.
20. F Ungaro R d'Emmanuele di Villa Bianca C Giovino A Miro R Sorrentino F Quaglia, et al. 2009 Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs J Control Release 135 1 25 34 19154761 10.1016/j.jconrel.2008.12.011 1:CAS:528:DC%2BD1MXjtFejurs%3D
21. F Ungaro G De Rosa A Miro F Quaglia MI La Rotonda 2006 Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs Eur J Pharm Sci 28 5 423 432 16806857 10.1016/j.ejps.2006.05.005 1:CAS:528:DC%2BD28XntFWrtbw%3D (Pubitemid 44038350)
22. MB Davidson G Bate P Kirkpatrick 2005 Exenatide Nat Rev Drug Discov 4 9 713 714 16178120 10.1038/nrd1828 1:CAS:528:DC%2BD2MXpslaqsLY%3D (Pubitemid 43090485)
23. CM Edwards SA Stanley R Davis AE Brynes GS Frost LJ Seal, et al. 2001 Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am J Physiol 281 1 155 161
24. ME Keegan JL Falcone TC Leung WM Saltzman 2004 Biodegradable microspheres with enhanced capacity for covalently bound surface ligands Macromolecules 37 26 9779 9784 10.1021/ma049470u 1:CAS:528:DC%2BD2cXpvF2kt70%3D (Pubitemid 40079964)
25. HJ Chung HK Kim JJ Yoon TG Park 2006 Heparin immobilized porous PLGA microspheres for angiogenic growth factor delivery Pharm Res 23 8 1835 1841 16858650 10.1007/s11095-006-9039-9 1:CAS:528:DC%2BD28XnvVymtro%3D (Pubitemid 44200547)
26. SY Chae CH Jin JH Shin S Son TH Kim S Lee, et al. 2010 Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs J Control Release 142 2 206 213 19900495 10.1016/j.jconrel.2009.10.025 1:CAS:528:DC%2BC3cXhvFehurg%3D
27. SY Chae YG Choi S Son SY Jung DS Lee KC Lee 2010 The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics J Control Release 144 1 10 16 20093159 10.1016/j.jconrel.2010.01.024 1:CAS:528: DC%2BC3cXlsVKhsLc%3D
28. I Kim TH Kim K Ma ES Lee D Kim KT Oh, et al. 2010 Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy Bioconjug Chem 21 8 1513 1519 20715855 10.1021/bc100143c 1:CAS:528:DC%2BC3cXpt1Cltb8%3D
29. TH Kim HH Jiang YS Youn CW Park SM Lim CH Jin, et al. 2011 Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution J Pharm Sci 100 2 482 491 20669330 10.1002/jps.22298 1:CAS:528:DC%2BC3cXhs1ags7bF
30. A Rawat QA Majumder F Ahsan 2008 Inhalable large porous microspheres of low molecular weight heparin: In vitro and in vivo evaluation J Control Release 128 3 224 232 18471921 10.1016/j.jconrel.2008.03.013 1:CAS:528: DC%2BD1cXmvVCrs7w%3D
31. M Morello CL Krone S Dickerson E Howerth WA Germishuizen YL Wong, et al. 2009 Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies Tuberculosis 89 5 371 377 19632897 10.1016/j.tube.2009.07.001 1:CAS:528:DC%2BC3cXhtlakur0%3D
32. H Kim H Park J Lee TH Kim ES Lee KT Oh, et al. 2011 Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes Biomaterials 32 6 1685 1693 21126761 10.1016/j.biomaterials.2010.10.045 1:CAS:528: DC%2BC3cXhs1SqtrfE
33. KC Lee SY Chae TH Kim S Lee ES Lee YS Youn 2009 Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent Regul Pept 152 1-3 101 107 18951927 10.1016/j.regpep.2008. 09.008 1:CAS:528:DC%2BD1cXhsV2lur7I
34. SY Chae YG Chun S Lee CH Jin ES Lee KC Lee, et al. 2009 Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers J Pharm Sci 98 4 1556 1567 18704955 10.1002/jps.21532 1:CAS:528:DC%2BD1MXktlSitrg%3D
35. K Naidoo H Rolfes K Easton S Moolman A Chetty W Richter, et al. 2008 An emulsion preparation for novel micro-porous polymeric hemi-shells Mater Lett 62 2 252 254 10.1016/j.matlet.2007.05.012 1:CAS:528:DC%2BD2sXhtlGmurnL (Pubitemid 350138151)
36. C Bosquillon C Lombry V Préat R Vanbever 2001 Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance J Control Release 70 3 329 339 11182203 10.1016/S0168-3659(00)00362-X 1:CAS:528:DC%2BD3MXhtV2mtbY%3D (Pubitemid 32155456)
37. G Pilcer K Amighi 2010 Formulation strategy and use of excipients in pulmonary drug delivery Int J Pharm 392 1-2 1 19 20223286 10.1016/j.ijpharm. 2010.03.017 1:CAS:528:DC%2BC3cXmtVGku7g%3D
38. AH Chow HH Tong P Chattopadhyay BY Shekunov 2007 Particle engineering for pulmonary drug delivery Pharm Res 24 3 411 437 17245651 10.1007/s11095-006- 9174-3 1:CAS:528:DC%2BD2sXhslWju7Y%3D (Pubitemid 46295160)
39. R Vanbever JD Mintzes J Wang J Nice D Chen R Batycky, et al. 1999 Formulation and physical characterization of large porous particles for inhalation Pharm Res 16 11 1735 1742 10571280 10.1023/A:1018910200420 1:CAS:528:DyaK1MXnt1GgsLw%3D (Pubitemid 29530407)
40. F Kratz 2008 Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J Control Release 132 3 171 183 18582981 10.1016/j.jconrel.2008.05.010 1:CAS:528:DC%2BD1cXhsVensLvP
41. GL Baker A Gupta ML Clark BR Valenzuela LM Staska SJ Harbo, et al. 2008 Inhalation toxicity and lung toxicokinetics of C60 fullerene nanoparticles and microparticles Toxicol Sci 101 122 131 17878152 10.1093/toxsci/kfm243 1:CAS:528:DC%2BD2sXhsVWgsLzO (Pubitemid 350239016)
42. YC Huang A Vieira KL Huang MK Yeh CH Chiang 2005 Pulmonary inflammation caused by chitosan microparticles J Biomed Mater Res A 75 283 287 16059899 1:STN:280:DC%2BD2MrjvVOqtQ%3D%3D (Pubitemid 41463896)
43. SE Fineberg T Kawabata D Finco-Kent C Liu A Krasner 2005 Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial J Clin Endocrinol Metab 90 3287 3294 15741258 10.1210/jc.2004-2229 1:CAS:528:DC%2BD2MXkvFClsbo%3D (Pubitemid 41014288)